CN103108631B - 用于治疗疼痛的联合药物 - Google Patents

用于治疗疼痛的联合药物 Download PDF

Info

Publication number
CN103108631B
CN103108631B CN201180029405.2A CN201180029405A CN103108631B CN 103108631 B CN103108631 B CN 103108631B CN 201180029405 A CN201180029405 A CN 201180029405A CN 103108631 B CN103108631 B CN 103108631B
Authority
CN
China
Prior art keywords
pain
combination
dimethylamino
methyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180029405.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN103108631A (zh
Inventor
K.席内
P.布隆斯芬克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42395008&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103108631(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Publication of CN103108631A publication Critical patent/CN103108631A/zh
Application granted granted Critical
Publication of CN103108631B publication Critical patent/CN103108631B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201180029405.2A 2010-06-15 2011-06-14 用于治疗疼痛的联合药物 Expired - Fee Related CN103108631B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10006202.5 2010-06-15
EP10006202 2010-06-15
PCT/EP2011/002905 WO2011157391A1 (en) 2010-06-15 2011-06-14 Pharmaceutical combination for the treatment of pain

Publications (2)

Publication Number Publication Date
CN103108631A CN103108631A (zh) 2013-05-15
CN103108631B true CN103108631B (zh) 2015-08-26

Family

ID=42395008

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180029405.2A Expired - Fee Related CN103108631B (zh) 2010-06-15 2011-06-14 用于治疗疼痛的联合药物

Country Status (29)

Country Link
US (3) US8846765B2 (enExample)
EP (2) EP2992877A1 (enExample)
JP (3) JP6133772B2 (enExample)
KR (1) KR101831616B1 (enExample)
CN (1) CN103108631B (enExample)
AR (1) AR081931A1 (enExample)
AU (2) AU2011267474B2 (enExample)
BR (1) BR112012031836A2 (enExample)
CA (1) CA2796774C (enExample)
CL (1) CL2012002551A1 (enExample)
CO (1) CO6602157A2 (enExample)
CY (1) CY1117118T1 (enExample)
DK (1) DK2582366T3 (enExample)
EC (2) ECSP12012217A (enExample)
ES (1) ES2560676T3 (enExample)
HK (1) HK1215787A1 (enExample)
HR (1) HRP20151327T1 (enExample)
HU (1) HUE026619T2 (enExample)
IL (1) IL221926A (enExample)
MX (1) MX2012014482A (enExample)
NZ (1) NZ602625A (enExample)
PE (2) PE20130243A1 (enExample)
PL (1) PL2582366T3 (enExample)
PT (1) PT2582366E (enExample)
RS (1) RS54439B1 (enExample)
RU (2) RU2589692C2 (enExample)
SI (1) SI2582366T1 (enExample)
WO (1) WO2011157391A1 (enExample)
ZA (1) ZA201208646B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6133772B2 (ja) 2010-06-15 2017-05-24 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 痛み治療用の医薬配合物
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
WO2013138322A1 (en) * 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
RS59687B1 (sr) 2013-01-22 2020-01-31 Vistagen Therapeutics Inc Oblici doziranja i terapeutske primene l-4-hlorkinurenina
AU2014240102A1 (en) 2013-03-15 2015-09-17 Janssen Pharmaceutica Nv Pharmaceutical composition of S-ketamine hydrochloride
CN103655523A (zh) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 他喷他多组合物
MX2016014581A (es) * 2014-05-06 2018-02-16 Univ Northwestern Composiciones de compuestos que modulan nmdar.
CA2957926A1 (en) 2014-08-13 2016-02-18 Janssen Pharmaceutica Nv Method for the treatment of depression
AU2015318123A1 (en) 2014-09-15 2017-03-30 Janssen Pharmaceutica Nv Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
CN107847469A (zh) 2015-06-27 2018-03-27 美国神农制药责任有限公司 氯胺酮透皮递送系统
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
IL319020A (en) 2017-12-22 2025-04-01 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
WO2019200345A1 (en) 2018-04-12 2019-10-17 Anavex Life Sciences Corp. A2-73 crystalline polymorph compositions of matter and methods of use thereof
WO2020178653A1 (en) 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1125221A (zh) * 1994-07-23 1996-06-26 格吕伦塔尔有限公司 具有药理效果的1-苯基-3-二甲氨基丙烷化合物
US6248789B1 (en) * 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
WO2003053427A1 (de) * 2001-12-21 2003-07-03 Grünenthal GmbH Verwendung von (+)-(1s,2s)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol als antiemetikum
CN1607947A (zh) * 2001-10-24 2005-04-20 格吕伦塔尔有限公司 包含3－(3－二甲基氨基－1－乙基－2－甲基－丙基)苯酚并能提供活性成分的延迟释放的药物
WO2009094563A2 (en) * 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
WO2010025931A2 (en) * 2008-09-05 2010-03-11 Grünenthal GmbH Pharmaceutical combination

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
US6007841A (en) * 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
WO2000003716A1 (en) 1998-07-16 2000-01-27 Memorial Sloan-Kettering Cancer Center Topical compositions comprising an opioid analgesic and an nmda antagonist
DE10005302A1 (de) * 2000-02-07 2002-01-17 Gruenenthal Gmbh Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
JP2003201254A (ja) * 2001-12-28 2003-07-18 Hisamitsu Pharmaceut Co Inc 鎮痛剤活性増強剤の治療上有効な血中濃度を維持するための製剤
JP2003210254A (ja) * 2002-01-18 2003-07-29 Nihon Form Service Co Ltd 車椅子専用ラック
US20060240128A1 (en) 2002-09-09 2006-10-26 Schlagheck Thomas G Combined immediate release and extended release analgesic composition
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US20090082466A1 (en) * 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
PL2012763T3 (pl) 2006-04-28 2011-08-31 Gruenenthal Gmbh Kombinacja farmaceutyczna zawierająca 3-(3-dimetyloamino-1-etylo-2-metylo-propylo)-fenol i NSAID
WO2007128413A1 (en) 2006-04-28 2007-11-15 Grünenthal GmbH Pharmaceutical combination comprising 3- ( 3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and paracetamol
US20070254960A1 (en) 2006-04-28 2007-11-01 Gruenenthal Gmbh Pharmaceutical combination
EP1857463A1 (en) 2006-05-03 2007-11-21 Ebewe Pharma Ges.m.b.H. Nfg. KG Peptide having neuroprotective effects
WO2007141018A1 (en) 2006-06-08 2007-12-13 Schwarz Pharma Ag Therapeutic combination for painful medical conditions
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007012165A1 (de) * 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
CN102065852B (zh) * 2007-11-23 2015-06-17 格吕伦塔尔有限公司 他喷他多组合物
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
JP6133772B2 (ja) 2010-06-15 2017-05-24 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 痛み治療用の医薬配合物
MX2013003354A (es) 2010-09-21 2013-06-24 Purdue Pharma Lp Analogos de buprenorfina.
CA2991216C (en) 2010-12-22 2020-04-28 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
EA024193B1 (ru) 2011-03-04 2016-08-31 Грюненталь Гмбх Фармацевтическая композиция на водной основе, предназначенная для парентерального введения тапентадола
MX2014011855A (es) 2012-04-17 2016-09-09 Purdue Pharma Lp Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1125221A (zh) * 1994-07-23 1996-06-26 格吕伦塔尔有限公司 具有药理效果的1-苯基-3-二甲氨基丙烷化合物
US6248789B1 (en) * 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
CN1607947A (zh) * 2001-10-24 2005-04-20 格吕伦塔尔有限公司 包含3－(3－二甲基氨基－1－乙基－2－甲基－丙基)苯酚并能提供活性成分的延迟释放的药物
WO2003053427A1 (de) * 2001-12-21 2003-07-03 Grünenthal GmbH Verwendung von (+)-(1s,2s)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol als antiemetikum
WO2009094563A2 (en) * 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
WO2010025931A2 (en) * 2008-09-05 2010-03-11 Grünenthal GmbH Pharmaceutical combination

Also Published As

Publication number Publication date
KR20130111945A (ko) 2013-10-11
HRP20151327T1 (hr) 2016-01-01
ECSP12012217A (es) 2012-11-30
JP2017141277A (ja) 2017-08-17
JP6133772B2 (ja) 2017-05-24
PL2582366T3 (pl) 2016-04-29
CN103108631A (zh) 2013-05-15
CO6602157A2 (es) 2013-01-18
AU2016219643A1 (en) 2016-09-15
RU2589692C2 (ru) 2016-07-10
MX2012014482A (es) 2013-02-21
CY1117118T1 (el) 2017-04-05
US20110306674A1 (en) 2011-12-15
WO2011157391A1 (en) 2011-12-22
EP2582366B1 (en) 2015-10-28
RU2016119041A (ru) 2017-11-20
AU2016219643B2 (en) 2018-04-12
AU2011267474A1 (en) 2013-01-10
JP6423036B2 (ja) 2018-11-14
US20170333369A1 (en) 2017-11-23
US20140309311A1 (en) 2014-10-16
HK1184370A1 (zh) 2014-01-24
CL2012002551A1 (es) 2012-11-09
IL221926A (en) 2015-08-31
RU2013101515A (ru) 2014-07-20
EP2992877A1 (en) 2016-03-09
HUE026619T2 (en) 2016-06-28
PE20160531A1 (es) 2016-06-05
SI2582366T1 (sl) 2016-02-29
JP6197007B2 (ja) 2017-09-13
RS54439B1 (sr) 2016-06-30
EP2582366A1 (en) 2013-04-24
AR081931A1 (es) 2012-10-31
US8846765B2 (en) 2014-09-30
AU2011267474B2 (en) 2016-05-26
ECSP19047259A (es) 2019-07-31
KR101831616B1 (ko) 2018-04-04
NZ602625A (en) 2014-03-28
JP2013528629A (ja) 2013-07-11
PT2582366E (pt) 2016-01-26
JP2015232015A (ja) 2015-12-24
BR112012031836A2 (pt) 2016-11-08
RU2675261C2 (ru) 2018-12-18
CA2796774A1 (en) 2011-12-22
HK1215787A1 (en) 2016-09-15
CA2796774C (en) 2020-06-02
ES2560676T3 (es) 2016-02-22
ZA201208646B (en) 2013-09-25
DK2582366T3 (en) 2015-12-07
PE20130243A1 (es) 2013-03-22
US10813890B2 (en) 2020-10-27

Similar Documents

Publication Publication Date Title
CN103108631B (zh) 用于治疗疼痛的联合药物
CN102159284B (zh) 3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和抗癫痫药的联合药物
JP5496653B2 (ja) ３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）−フェノール、およびパラセタモールを含む医薬の組合せ
US20070254960A1 (en) Pharmaceutical combination
HK1184370B (en) Pharmaceutical combination for the treatment of pain

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150826

Termination date: 20210614